Patrick G. Enright, Director at Jazz Pharmaceuticals plc (JAZZ), sold 352 shares at $133.19 ($47K) on 2017-11-17, disclosed to the SEC on 2017-11-21.
Scheduled sale ($47k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ZBIO | BUY | 2025-10-14 | $2.5M | — | Filing → |
| VERA | BUY | 2025-06-25 | $10.6M | — | Filing → |
| BIOA | BUY | 2024-09-27 | $7.2M | — | Filing → |